Retatrutide
更新时间：2026-05-21 21:15:23
| 常用名 | LY3437943 | CAS号 | 2381089-83-2 |
|---|---|---|---|
| 价格 | $432.12/10mg $6847.04/1g | 纯度 | 98.77% |
| 备货期 | 3天 | 库存 | 现货 |
| 产品网页 | http://www.zhaokebio.com | ||
| 产品详情（用途，包装等）
Retatrutide (development code LY3437943) is a first-in-class triple hormone receptor agonist peptide developed by Eli Lilly and Company, designed for the treatment of obesity and type 2 diabetes. It simultaneously activates three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG), delivering unprecedented synergistic effects on body weight reduction, glycemic control, and metabolic health. Retatrutide is a 39-amino-acid linear peptide engineered from the native oxyntomodulin sequence with strategic amino acid substitutions to optimize receptor binding profiles. The peptide is conjugated to a C20 fatty diacid moiety via a gamma-Glu-AEEA-Lys linker at Lys20, enabling strong albumin binding and an extended half-life of approximately 6 days, which supports once-weekly subcutaneous administration. Clinical trials have demonstrated record-breaking efficacy: Phase 2 trials showed up to 24.2% mean weight reduction at 48 weeks, while Phase 3 TRIUMPH-4 trial demonstrated 28.7% weight loss (71.2 lbs) at 68 weeks in participants with obesity and knee osteoarthritis. Shenzhen Zhaoke Biotechnology Co., Ltd. provides high-purity Retatrutide API (CAS No.: 2381089-83-2) with comprehensive analytical documentation for global pharmaceutical developers and research institutions. Key Selling Points: Triple Receptor Agonism-Simultaneously activates GIP, GLP-1, and glucagon receptors, delivering synergistic metabolic benefits that surpass single- or dual-agonist therapies. The unique triple mechanism enables superior weight loss and glycemic control. Breakthrough Weight Loss Efficacy-Phase 2: 24.2% weight loss at 48 weeks; Phase 3 TRIUMPH-4: 28.7% (71.2 lbs) at 68 weeks. Over 90% of participants achieved ≥10% weight loss at 12 mg dose. The weight loss curve had not plateaued at trial end. Osteoarthritis Pain Relief-Phase 3 TRIUMPH-4 demonstrated 75.8% reduction in WOMAC pain scores. Over 12% of treated participants became completely free of knee pain, significantly outperforming semaglutide (42% pain reduction). Once-Weekly Dosing-C20 fatty diacid conjugation enables albumin binding with a ~6-day half-life, supporting convenient once-weekly subcutaneous injection for improved patient adherence. Superior Metabolic Profile-Reduces A1C by up to 2.0%, lowers non-HDL cholesterol and triglycerides, and decreases systolic blood pressure. Total fat mass reduced by 26.1% with comparable lean mass preservation. Well-Tolerated Safety-Side effect profile consistent with GLP-1/GIP receptor agonists. Gastrointestinal events (nausea, diarrhea, vomiting) are the most common and typically transient. No new safety signals identified. |
- 上海阿拉丁生化科技股份有限公司
- 上海市 上海市 浦东新区
- 产品名：Retatrutide 钠盐
- 价格： ￥7999.9/10mg ￥2299.9/1mg ￥5999.9/5mg
- 纯度：97.0%
- 备货期：1天
- 联系人：阿拉丁
2881459338
复制
- 武汉敬康恩生物医药科技有限公司
- 湖北省 武汉市 东西湖区
- 产品名：雷塔鲁肽
- 价格： ￥1.0/1g ￥1.0/5g
- 纯度：98.0%
- 备货期：1天
- 联系人：周经理
1092734927
复制
15871494362
复制
- 上海化源世纪贸易有限公司
- 上海市 上海市 普陀区
- 产品名：Retatrutide
- 价格：
- 纯度：99.0%
- 备货期：10天
- 联系人：徐经理
351666998
复制
13311869306
复制
查看所有供应商和价格请点击：